Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp (IMCC) provides premium medical cannabis products in regulated international markets, with operational hubs in Israel and Germany. This news hub offers investors and industry stakeholders centralized access to official updates and market developments.
Track all corporate announcements including regulatory milestones, strategic partnerships, and operational expansions. Our curated collection ensures timely access to earnings reports, product launches, and compliance achievements that shape this medical cannabis leader's trajectory.
Discover updates on IMCC's EU-GMP certified operations, Focus Medical Herbs collaboration in Israel, and Adjupharm GmbH's German distribution network. Content spans supply chain innovations, licensing agreements, and quality control advancements critical to medical cannabis operations.
Bookmark this page for verified updates from a company maintaining strict adherence to international medical standards. Stay informed about IMCC's data-driven approach to cultivation and distribution in complex regulatory environments.
IM Cannabis Corp. (CSE: IMCC, NASDAQ: IMCC) reported Q3 2022 revenues of $14.2 million, up 78% year-over-year, with a 12% sequential organic growth. Gross profit reached $2.8 million with a 20% gross margin. The company announced its exit from the Canadian market to focus on the Israeli and German markets. Total assets fell to $129.1 million, a 55% decline due to goodwill impairment. The company will consolidate shares to regain compliance with NASDAQ. A conference call will discuss detailed results.
IM Cannabis Corp. (NASDAQ: IMCC) announces its strategic exit from the Canadian cannabis market to focus on growth in Israel and Germany, aiming for profitability in 2023. The company has filed for creditor protection under the Canadian Companies' Creditors Arrangement Act (CCAA) for its subsidiary, Trichome Financial, while maintaining operations in its other markets. The restructuring aims to enhance efficiency and capitalize on market demand, leveraging strong sourcing skills and strategic alliances.
IM Cannabis Corp (CSE: IMCC, NASDAQ: IMCC) will release its third-quarter financial results for 2022 on November 14, 2022, before market opens. The results will be discussed in a Zoom conference at 9:00 AM ET, followed by a Q&A session for investors. IM Cannabis operates in significant cannabis markets including Israel, Canada, and Germany, focusing on delivering premium products to both medical and recreational consumers.
IM Cannabis Corp. (NASDAQ: IMCC) announced that its Roma strain was voted Israel's Favourite Strain of the Month for August 2022, highlighting its market momentum following recent restructuring initiatives. The Roma strain, known for its therapeutic benefits, sold 100 kilograms in Israel in August. IMC's efforts include expanding product offerings and streamlining operations, establishing itself as a leader in the Israeli medical cannabis market with over 25 new SKUs launched in the past year. CEO Oren Shuster emphasized the success of these initiatives in enhancing product quality and patient satisfaction.
Avant Brands and IM Cannabis Corp. announced on October 12, 2022, a Licensing Agreement permitting IMC exclusive rights to launch the BLKMKT brand in Israel's medical cannabis market. This agreement enhances their collaboration, allowing IMC to utilize Avant’s premium cannabis products in its offerings. The partnership aims to meet the increasing demand for high-quality cannabis in Israel and strengthens IMC’s leadership in the ultra-premium segment. Avant will provide cannabis grown in Canada, ensuring compliance with regulatory standards.
Avant Brands (OTCQX: AVTBF) and IM Cannabis Corp. (NASDAQ: IMCC) have signed an international trademark licensing agreement allowing IMC exclusive rights to launch the BLKMKT brand in Israel's medical cannabis market. This agreement underlines the robust partnership between the two companies, enhancing IMC's premium product portfolio with Avant's high-quality strains. As part of their evolving collaboration, IMC aims to solidify its standing in the ultra-premium cannabis segment in Israel, catering to a growing demand for top-tier indoor cannabis products.
IM Cannabis Corp. (NASDAQ: IMCC) has completed the second tranche of a non-brokered private placement, issuing 1,112,504 common shares at USD$0.50 each, raising a total of USD$556,252. This brings the total raised from the offering to approximately USD$3 million. The proceeds will be used for general working capital purposes. The transaction involved insider participation from Executive Chairman Marc Lustig, exempting the company from certain minority approval requirements due to the market capitalization less than 25%. All shares are subject to a four-month hold period.
SNDL has successfully completed its first international export of approximately 167 kilograms of premium dried cannabis flower from Canada to Israel in partnership with IM Cannabis Corp. This export is part of a larger agreement to export a total of 1,000 kilograms for distribution in the Israeli medical cannabis market. SNDL aims to expand its international presence and increase revenue from cannabis operations. The collaboration with IMC is expected to enhance the supply chain and product quality in the emerging global cannabis markets.
IM Cannabis Corp. (NASDAQ: IMCC) announced the appointment of Einat Zakariya and Moti Marcus to its board of directors, replacing Vivian Bercovici and Haleli Barath. Zakariya, a CEO in real estate with experience on multiple boards, and Marcus, a CEO in metals with a strong financial background, bring substantial expertise. CEO Oren Shuster highlighted their leadership as pivotal for IMC's growth. The company continues to strengthen its position in the cannabis market across Israel, Canada, and Germany.
On September 8, 2022, Rafael Gabay, a notable shareholder of IM Cannabis Corp. (IMCC), announced his acquisition of 613,496 Common Shares through a non-brokered private placement of 4,887,496 shares at USD$0.50 each, totaling USD$2,443,748. Following this transaction, Mr. Gabay's ownership increased to 8,704,216 shares, representing approximately 11.67% of IMCC's total shares. This marks a slight rise from his previous ownership of 11.61%. The acquisition is intended for general investment purposes and may lead to future transactions, subject to market conditions.